11 studies found for:    vedolizumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Placebo
2 Recruiting Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Condition: Healthy
Interventions: Drug: Vedolizumab SC;   Drug: Vedolizumab IV
3 Completed
Has Results
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
4 Recruiting Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
5 Recruiting Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
6 Completed
Has Results
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Condition: Inflammatory Bowel Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo;   Biological: Hepatitis B vaccine;   Biological: Oral cholera vaccine
7 Completed
Has Results
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
8 Completed
Has Results
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
9 Completed
Has Results
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab;   Other: Placebo
10 Active, not recruiting An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
11 Completed Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
Condition: Crohn's Disease
Interventions: Drug: LDP-02;   Drug: Placebo

Indicates status has not been verified in more than two years